Tibolone as Hormonal Therapy and Neuroprotective Agent

Juan Pablo Del Río; Santiago Molina; Oscar Hidalgo-Lanussa; Luis Miguel Garcia-Segura; George E. Barreto

doi:10.1016/j.tem.2020.04.007

Tibolone as Hormonal Therapy and Neuroprotective Agent

Juan Pablo Del Río
, Santiago Molina
, Oscar Hidalgo-Lanussa
, Luis Miguel Garcia-Segura
, George E. Barreto

Reproductive Health Research Institute
Universidad de Chile
Santiago
Tallahassee Community College
Universidad Javeriana
Instituto Cajal, CSIC
Instituto de Salud Carlos III

Research output: Contribution to journal › Review article › peer-review

Abstract

Tibolone (TIB), a selective tissue estrogenic activity regulator (STEAR) in clinical use by postmenopausal women, activates hormonal receptors in a tissue-specific manner. Estrogenic activity is present mostly in the brain, vagina, and bone, while the inactive forms predominate in the endometrium and breast. Conflicting literature on TIB's actions has been observed. While it has benefits for vasomotor symptoms, bone demineralization, and sexual health, a higher relative risk of hormone-sensitive cancer has been reported. In the brain, TIB can improve mood and cognition, neuroinflammation, and reactive gliosis. This review aims to discuss the systemic effects of TIB on peri- and post-menopausal women and its role in the brain. We suggest that TIB is a hormonal therapy with promising neuroprotective properties.

Original language	English
Pages (from-to)	742-759
Number of pages	18
Journal	Trends in Endocrinology and Metabolism
Volume	31
Issue number	10
DOIs	https://doi.org/10.1016/j.tem.2020.04.007
Publication status	Published - Oct 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being
SDG 5 Gender Equality

Keywords

breast
central nervous system
hormonal therapy
neuroprotection
tibolone
uterus

Access to Document

10.1016/j.tem.2020.04.007

Cite this

@article{50a60534641a4f2195654257ac1731ce,

title = "Tibolone as Hormonal Therapy and Neuroprotective Agent",

abstract = "Tibolone (TIB), a selective tissue estrogenic activity regulator (STEAR) in clinical use by postmenopausal women, activates hormonal receptors in a tissue-specific manner. Estrogenic activity is present mostly in the brain, vagina, and bone, while the inactive forms predominate in the endometrium and breast. Conflicting literature on TIB's actions has been observed. While it has benefits for vasomotor symptoms, bone demineralization, and sexual health, a higher relative risk of hormone-sensitive cancer has been reported. In the brain, TIB can improve mood and cognition, neuroinflammation, and reactive gliosis. This review aims to discuss the systemic effects of TIB on peri- and post-menopausal women and its role in the brain. We suggest that TIB is a hormonal therapy with promising neuroprotective properties.",

keywords = "breast, central nervous system, hormonal therapy, neuroprotection, tibolone, uterus",

author = "\{Del R{\'i}o\}, \{Juan Pablo\} and Santiago Molina and Oscar Hidalgo-Lanussa and Garcia-Segura, \{Luis Miguel\} and Barreto, \{George E.\}",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Ltd",

year = "2020",

month = oct,

doi = "10.1016/j.tem.2020.04.007",

language = "English",

volume = "31",

pages = "742--759",

journal = "Trends in Endocrinology and Metabolism",

issn = "1043-2760",

number = "10",

}

TY - JOUR

T1 - Tibolone as Hormonal Therapy and Neuroprotective Agent

AU - Del Río, Juan Pablo

AU - Molina, Santiago

AU - Hidalgo-Lanussa, Oscar

AU - Garcia-Segura, Luis Miguel

AU - Barreto, George E.

PY - 2020/10

Y1 - 2020/10

N2 - Tibolone (TIB), a selective tissue estrogenic activity regulator (STEAR) in clinical use by postmenopausal women, activates hormonal receptors in a tissue-specific manner. Estrogenic activity is present mostly in the brain, vagina, and bone, while the inactive forms predominate in the endometrium and breast. Conflicting literature on TIB's actions has been observed. While it has benefits for vasomotor symptoms, bone demineralization, and sexual health, a higher relative risk of hormone-sensitive cancer has been reported. In the brain, TIB can improve mood and cognition, neuroinflammation, and reactive gliosis. This review aims to discuss the systemic effects of TIB on peri- and post-menopausal women and its role in the brain. We suggest that TIB is a hormonal therapy with promising neuroprotective properties.

AB - Tibolone (TIB), a selective tissue estrogenic activity regulator (STEAR) in clinical use by postmenopausal women, activates hormonal receptors in a tissue-specific manner. Estrogenic activity is present mostly in the brain, vagina, and bone, while the inactive forms predominate in the endometrium and breast. Conflicting literature on TIB's actions has been observed. While it has benefits for vasomotor symptoms, bone demineralization, and sexual health, a higher relative risk of hormone-sensitive cancer has been reported. In the brain, TIB can improve mood and cognition, neuroinflammation, and reactive gliosis. This review aims to discuss the systemic effects of TIB on peri- and post-menopausal women and its role in the brain. We suggest that TIB is a hormonal therapy with promising neuroprotective properties.

KW - breast

KW - central nervous system

KW - hormonal therapy

KW - neuroprotection

KW - tibolone

KW - uterus

UR - https://www.scopus.com/pages/publications/85085930852

U2 - 10.1016/j.tem.2020.04.007

DO - 10.1016/j.tem.2020.04.007

M3 - Review article

C2 - 32507541

AN - SCOPUS:85085930852

SN - 1043-2760

VL - 31

SP - 742

EP - 759

JO - Trends in Endocrinology and Metabolism

JF - Trends in Endocrinology and Metabolism

IS - 10

ER -

Tibolone as Hormonal Therapy and Neuroprotective Agent

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this